Combining GO-Y022 with the glycolysis inhibitor 2-DG decreases lactate production and Treg infiltration, achieving 82% tumor regression in HER2-negative PDX models while enhancing CD8+ T-cell infiltration (150). Here, ERBB2 is linked to neoplasm.